Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1990 1
1991 2
1992 1
1993 4
1994 1
1996 1
1997 3
1998 3
1999 4
2000 3
2001 5
2002 5
2003 5
2004 6
2005 8
2006 8
2007 9
2008 14
2009 12
2010 18
2011 14
2012 12
2013 13
2014 21
2015 21
2016 20
2017 23
2018 13
2019 17
2020 17
2021 19
2022 20
2023 21
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Results by year

Filters applied: . Clear all
Page 1
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. Narayanaswami P, et al. Among authors: verschuuren j. Neurology. 2021 Jan 19;96(3):114-122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. Neurology. 2021. PMID: 33144515 Free PMC article. Review.
Myasthenia gravis.
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Gilhus NE, et al. Among authors: verschuuren jjgm. Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. Nat Rev Dis Primers. 2019. PMID: 31048702 Review.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: verschuuren j. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
International consensus guidance for management of myasthenia gravis: Executive summary.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. Sanders DB, et al. Among authors: verschuuren j. Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Neurology. 2016. PMID: 27358333 Free PMC article. Review.
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J. Graus F, et al. Among authors: verschuuren jj. Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):e1014. doi: 10.1212/NXI.0000000000001014. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34006622 Free PMC article.
Myasthenia gravis-Pathophysiology, diagnosis, and treatment.
Tannemaat MR, Huijbers MG, Verschuuren JJGM. Tannemaat MR, et al. Among authors: verschuuren jjgm. Handb Clin Neurol. 2024;200:283-305. doi: 10.1016/B978-0-12-823912-4.00026-8. Handb Clin Neurol. 2024. PMID: 38494283 Review.
Lambert-Eaton myasthenic syndrome.
Lipka AF, Verschuuren JJGM. Lipka AF, et al. Among authors: verschuuren jjgm. Handb Clin Neurol. 2024;200:307-325. doi: 10.1016/B978-0-12-823912-4.00012-8. Handb Clin Neurol. 2024. PMID: 38494285 Review.
Randomized Trial of Thymectomy in Myasthenia Gravis.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Wolfe GI, et al. Among authors: verschuuren jj. N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. N Engl J Med. 2016. PMID: 27509100 Free PMC article. Clinical Trial.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: verschuuren jjgm. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
313 results